Sample Totals for June 2026:
Qualitative Results: 345 (West), 850 (East), 1195 (All)
Quantitative Results: 180 (Total)
Samples analyzed and included in these counts are voluntarily submitted samples that were collected and provided by public health, harm reduction, or law enforcement agencies from across the country. The trends observed in these samples may not be representative of broader trends within the United States drug supply.
Prevalence & Three Month Trends
Samples Collected in June 2026
The tables below show the percent of samples containing select drugs (top) and adulterants (bottom). Percentages for West Coast samples, East Coast samples, and all samples are provided. A darker purple cell indicates a higher percentage.
The 3-Month Trend column has sparkline plots showing the percentage of samples containing the compound over the last three months. The right-most point on the plot corresponds to the percentage in the All Samples column. The center and left points are the percentages for May and April 2026, respectively.
Important Notes:
- Determination of salt form or distinction between salt and free base was not completed.
- For some compounds, such as fluorofentanyl, isomer determination was not completed. For instances where isomer determination was completed, the specific isomer is listed.
- Many samples contain multiple substances therefore summed percentages may exceed 100%.
Drug Prevalence
Adulterant Prevalence
 Compound Abbreviations
- 2-MMC: 2-Methylmethcathinone
- 4-MMC: 4-Methylmethcathinone
- alpha-PVP: alpha-Pyrrolidinovalerophenone
- BTMPS: Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate
- iso-PV8: alpha-Pyrrolidinoisoheptanophenone
- MDMA: Methylenedioxymethamphetamine
Co-Detection for Cocaine, Fentanyl, & Methamphetamine
Samples Collected in June 2026
The following tables provide information on compounds commonly co-detected with cocaine (top), fentanyl (center), and methamphetamine (bottom). In each table, the listed values reflect the percentage of cocaine, fentanyl, or methamphetamine containing samples that also contained the listed compound. The top ten co-detected compounds are provided for cocaine and methamphetamine while up to the top twenty co-detected compounds are provided for fentanyl.
Important Notes:
- Samples collected from drug use paraphernalia (e.g. syringe, cooker, straw, pipe) have been excluded from these counts due to the high probability of co-use with multiple substances.
- It is possible that the listed drug is a contaminant or minor component in a substance with a different main drug. For instance, cocaine may be present as a contaminant in a fentanyl sample but included in the cocaine co-detection count.
- Byproducts and precursors are not included in the tables below.
- Many samples contain multiple substances therefore summed percentages may exceed 100%.
Cocaine Co-Detection (186 Samples)
 Fentanyl Co-Detection (232 Samples)
 Methamphetamine Co-Detection (108 Samples)
New Compounds Identified
Samples Collected in June 2026
In June, twelve new compounds were detected for the first time in RaDAR samples.
Important Notes:
- Compounds discussed here are those that have been newly detected in RaDAR samples. This does not mean that it is the first identification of the compound in the drug supply.
- Determination of salt form or distinction between salt and free base was not completed.
 |
|
N-propionitrile Brorphine, a synthetic opioid, was found in multiple East Coast samples that contained fentanyl, medetomidine, and other adulterants.
|
|
N-pyrrolidino Etonitazene, a synthetic opioid, was found in a single East Coast sample that contained multiple other nitazenes, fentanyl, and several adulterants.
|
|
 |
 |
|
N-pyrrolidino Metonitazene, a synthetic opioid, was found in a single East Coast sample that contained multiple other nitazenes, fentanyl, and several adulterants.
|
|
N-pyrrolidino Protonitazene, a synthetic opioid, was found in a single East Coast sample that contained multiple other nitazenes, fentanyl, and several adulterants.
|
|
 |
 |
|
Deschlorodemethyldiazepam, a benzodiazepine, was identified in multiple East Coast samples that contained fentanyl, gabapentin, xylazine, and other adulterants.
|
|
3-Methoxy PCP, an arylcyclohexylamine, was found in a single West Coast sample that contained no other compounds.
|
|
 |
 |
|
9-O-desmethyl Mitragynine, a kratom alkaloid, was found in a single West Coast sample that also contained 7-hydroxy mitragynine and mitragynine.
|
|
alpha-Methyl Tryptamine, a tryptamine, was found in multiple West Coast samples that contained other hallucinogens.
|
|
 |
 |
|
Fluoro-alpha-PHP, a synthetic cathinone, was found in multiple East Coast samples that also contained fentanyl, alpha-PVP, and isoPV8.
The positional isomer of fluoro-alpha-PHP has not yet been determined. (3- isomer shown)
|
|
Methamnetamine, an amphetamine, was found in a single West Coast sample that contained no other compounds.
|
|
 |
 |
|
O-PCE (deschloro-N-ethyl-Ketamine), an arylcyclohexylamine, was found in multiple West Coast samples that either contained no other compounds or contained proscaline.
|
|
Proscaline, a phenethylamine, was found in a single West Coast sample that also contained O-PCE.
|
|
 |
Sample Type Breakdown
Samples Collected in June 2026
The plot below provides a breakdown of the types of items from which samples were collected.
Important Notes:
- Item types with a <1% contribution have been grouped into the "Other" category.
Drug Product Quantitation Summary
Samples Collected in June 2026
The plot below provides information on the quantitative testing of select drug product samples. Blue dots indicate the minimum and maximum weight percentages across all samples. The purple diamond represents the median weight percentage for all samples containing the compound.
Important Notes:
- Quantitative values less than 0.5% by weight have been omitted.
- Listed values are reported as the free base of the compound. Correction factors for salt form have not been applied.
Recent Publications
Towards Increased Data Sharing and Standardization for Illicit Drug Analysis and Monitoring Workshop Report
The street drug supply in the United States is evolving at an unprecedented rate. Effectively addressing this epidemic, now driven largely by synthetic opioids, novel psychoactive substances, and poly substance use, requires diverse communities to share accurate, real-time intelligence. In June 2025, the National Institute of Standards and Technology (NIST) hosted the “Towards Increased Data Sharing and Standardization for Illicit Drug Analysis and Monitoring” workshop. This workshop brought together representatives from multiple communities directly involved in responding to the drug epidemic, including border interdiction, law enforcement, public health, forensic science, and clinical. Read More.
Needs and Research Gaps Surrounding Safe Handling of Synthetic Opioids and Other Emerging Compounds of Concern Workshop Report
With a street drug supply that contains increasingly potent compounds, those involved in the interdiction, analysis, and remediation of these samples continue to face numerous occupational safety challenges. This report synthesizes findings from a multi-community workshop that identified barriers to safe handling, including "hazard fatigue" affecting PPE compliance, a lack of standardized decontamination metrics, and technological lag in field detection of novel compounds and complex mixtures. Read More.
Trends in Fentanyl Adulteration from Rapid Drug Analysis and Research (RaDAR) Drug Checking Samples, January 2024 to January 2026
In recent years, the United States fentanyl market has experienced a significant increase in adulteration. Street fentanyl samples now often contain local anesthetics, industrial chemicals, veterinary sedatives and other drugs, making tracking more difficult and necessary. While traditional data sources, such as forensic data, often do not report non-controlled adulterants, a growing field of laboratory-based drug checking for public health programs is focused on providing near complete chemical insights into street drug samples. In this work, fentanyl adulteration trends from the National Institute of Standards and Technology’s (NIST) Rapid Drug Analysis and Research (RaDAR) program are examined. Summarizing data from samples collected between January 2024 and January 2026, the detection of α2-agonists, industrial chemicals, local anesthetics, fentanyl analogs, and other drugs in the fentanyl supply is discussed. Read More.
In the News
How the Federal Government is Tracking Changes in the Supply of Street Drugs.
"The National Institute of Standards and Technology's new harm reduction initiative is helping prevent needless deaths." Read More.
|
